CD4 and glioblastoma: Khan and colleagues investigated the efficacy of PD‐1 ICB, a CD40 agonist, and a combination of both in a CT2A glioblastoma mouse model that contained dysfunctional CD4+ T cells and was unresponsive to anti‐PD‐1 ICB.48